Best Oncology Companies in Gyeonggi-do, South Korea
The 42 best Oncology companies in Gyeonggi-do, South Korea in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Genexine.
Our analysis of 50 Oncology companies
$16.3b in tracked funding; 86% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Oncology companies in Gyeonggi-do
| # | Company | Last round | Disclosed funding | Employees | Founder | Tech stack | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Alpha Holdings Developer of cytokine based therapeutics | — | — | 125 | Hee Do Koo CEO | — | — | 58 patents Patents concentrated in construction | — |
| 2 | AZothBio R&D company focused on manufacturing of drugs for multiple therapeutic areas | — | — | 19 | — | — | — | 56 patents Small‑molecule kinase inhibitors and peptide delivery systems for intracellular cancer therapeutics | — |
| 3 | BeyondDx Provider of liquid biopsy-based multi-integrated analysis solution for cancer diagnostics | — | — | — | Sojin Jung CEO | — | — | — | — |
| 4 | C&C Research Laboratories Provides a portfolio of biotechnological research | — | — | — | Chun Jae-kwang CEO | JavaNaver Mapscore-js+3 | Top 50M | — | — |
| 5 | CreaGene Dendritic Cell Vaccine and drug delivery platform tech and therapeutics for Cancer and Inflammatory diseases | — | — | — | Jae Kwang Chun Co-CEO | JavaNaver Mapscore-js+3 | Top 50M | 64 patents Immunotherapy via engineered dendritic cells and antigen‑delivery peptides for vaccines and autoimmunity | — |
| 6 | D5 Therapeutics Developer of therapeutics for cancer treatment | — | — | — | Yongho Oh CEO | — | — | 57 patents Targeted small‑molecule ion‑channel/TLR modulators and cannabinoid nanoparticle delivery systems | — |
| 7 | DIGMBIO Developer of therapeutics for multiple diseases | — | — | 8 | Kim Min CEO | — | — | 16 patents Novel arabinose and isoquinolinone small‑molecule therapeutics for neurodegeneration and PARP‑1 inhibition | — |
| 8 | Drtech X-ray panels for digital radiography | — | — | 287 | — | PHPYouTubeGSAP+13 | Top 5M | 226 patents Portable X‑ray imaging systems with flexible detectors and advanced noise‑reduction processing | — |
Top 12 Oncology companies in Gyeonggi-do
#1
Series B · Seongnam-si, Gyeonggi-do · founded 2020 · 20 employees$15Mraised▾
Developer of drugs for the treatment of cancer and central nervous diseases. The company develops GPCR-targeted small-molecule drugs using artificial intelligence to treat neurological disorders, cognitive function, and cancer.
- Apr 2026Series B$15M
#2
Series D · Seongnam-si, Gyeonggi-do · founded 2016 · 34 employees$22Mraised▾
1ST Bio is developing therapies for treating neurodegenerative and immuno-oncological diseases. The lead candidate of the company, 1ST 102 is a tyrosine kinase enzyme inhibitor. It's in the preclinical phase which is used for treating Parkinson's Disease. Other candidates like 1ST-101 and 1ST-103 are in the discovery stage.
- Jan 2026Series D$22M
#3
Series B · Seongnam-si, Gyeonggi-do · founded 2017 · 19 employees$17.8Mraised▾
MediMabBio is a developer of immunotherapeutics for treating cancer. The company develops immuno-oncology drugs using its drug discovery platform with a combination of systems biology and immunological solutions to target solid tumors. The products pipeline includes immune checkpoint antibody (MMB-101) in lead optimization stage and immuno cytokine agents (MMB-201) in hit optimization stage.
- Oct 2025Series B$17.8M
#4
Public · Suwon-si, Gyeonggi-do · founded 2020 · 25 employees$33.8Mraised▾
Developer of antibody therapeutics to treat cancer and autoimmune diseases. The company has developed a platform technology called ePendy that can generate antibody therapeutics for the treatment of autoimmune diseases and cancer.
- Jul 2023Series B$15.5M
- Aug 2021Series A$14.7M
- Jan 2021Seed$3.6M
#5
Public · Seongnam-si, Gyeonggi-do · founded 2002$233Mraised▾
Developer of immunotherapeutics for treating orphan diseases, cancers & autoimmune disorders. The company has developed drug candidates for Growth Hormone Deficiencies, Cervical Cancers, and Anemias. Its technology is based on Fc fusion proteins and DNA Vaccines.
- Mar 2018Post IPO$233M
#6
Public · Seongnam-si, Gyeonggi-do · founded 2016 · 21 employees$60.5Mraised▾
Developer of monoclonal and specific antibody for cancer treatment. The company's lead antibody IMC-001 is currently in phase 1 of the clinical trial. The company has a pipeline of immune checkpoint antibodies against undisclosed targets for both hematological malignancies and solid tumors.
- Jan 2022Series B$20.5M
- Feb 2019Series A$40M
#7
Public · Seongnam-si, Gyeonggi-do · founded 2016 · 93 employees$65Mraised▾
ABL Bio is a Korean, clinical-stage biopharma developing immunotherapies for oncology and neurodegenerative diseases. Their first lead candidate is ABL001 a bispecific antibody targeting DII4 & VEGF and is indicated for solid tumors. The second bispecific antibody is ABL301, a BBB penetrating Bispecific antibody for targeting Alpha-Synuclein, and indicated for Parkinson's Disease and other synucleopathies. The company is developing 4 ADCs for various cancer indications (MM, AML, CLL, TNBC).
- Jun 2018Series C$65M
- 2016Seed—
#8
Series A · Suwon-si, Gyeonggi-do · founded 2021$16.4Mraised▾
Developer of antibody therapies to treat cancer and immune diseases. The company focuses on developing an antibody platform based on proprietary technology to develop cancer-targeted drugs. The flagship product of the company is CTN001 a human epidermal growth factor receptor 2 (HER2)-targeting antibody, to treat HER2-low-expressing breast cancer.
- Mar 2022Series A$16.4M
#9
Series B · Seongnam, Gyeonggi-do · founded 2021 · 15 employees$14.8Mraised▾
Developer of anticancer drugs using cancer metabolism. The company's lead product 'ASCA101' is a novel pharmaceutical composition for cancer treatment that inhibits the effects of cancer cell proliferation, invasion, and metastasis. Other drug candidates include MF03 for Cancer Acidosis and MF04 for Cachexia.
- Apr 2022Series B$14.8M
#10
Aprogen 🦄Late Stage · Seongnam-si, Gyeonggi-do · founded 2000 · 66 employees$30.7Mraised▾
Aprogen is a Korean Biotech that develops its own biologics and also biosimilars. It is developing biosimilar products for various biologics including infliximab, trastuzumab, adalimumab, and bevacizumab. In terms of novel biologics, it is developing AP185, AP216, and other new candidates targeted for vascular disease and oncology market. Currently, Aprogen can manufacture over 80 kg of APIs of biopharmaceuticals annually and it has undertaken construction of the second factory with annual manufacturing capacity over 2,000 kg of API and a fill-finish facility, which is expected to be completed by the end of 2017. The first lead candidate, AP185, is a fusion protein of the functional C-terminal domain of angiopoietin 1 (Ang1) and short coiled-coil domain of cartilage oligomeric matrix protein (COMP). AP185 indicated for damaged blood vessels caused by myocardial infarction, diabetic foot ulcer, and erectile dysfunction. The second lead candidate, AP216, is a fusion protein of angiopoietin binding domain of TIE2, Ig2 domain of VEGFR, and Fc domain of immunoglobulin G1. AP216 blocks angiogenic action in various cancers, such as ovarian and lung cancers, by effective suppression of
- May 2019PE$16.7M
- Jul 2012PE$14M
#11
Public · Suwon-si, Gyeonggi-do · founded 2013 · 62 employees$16Mraised▾
MedPacto, spun-off from Theragen Etex, (a specialized genomics company) is engaged in the development of small molecules for cancer. Their lead candidate which is currently undergoing Phase 1 trials is TEW-7197, an inhibitor of ALK-5 to block signal transduction by TGF-b and TEW-0201, an inhibitor of BRAF and c-RAF, which is in the preclinical stage. TEW-7197 was originally developed by the Ewha Woman's University with government support of the Program for Disease-Based Discovery of Global New Drug Candidates and was out-licensed from Ewha to MedPacto.
- Dec 2020Post IPO$90.2M
- 2018Series A$16M
#12
Series B · Seongnam-si, Gyeonggi-do · founded 2014 · 46 employees$13.5Mraised▾
Developer of AI-based diagnostic platform for cancer and cardiac diseases. The company's lead product MASTOCHECK is a proteomics-based blood test to detect breast cancer. Another product is a cardiovascular disease marker which is a non-invasive blood test that detects the biomarkers present in the blood.
- Jun 2021Series B$13.5M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Oncology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Oncology & Cancer Therapeutics is moving in South Korea
A read on the academic research around Oncology & Cancer Therapeutics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,493 South Korea-affiliated papers.
- Ministry of Education247
- Seoul National University134
- National Cancer Center127
- Sungkyunkwan University117
- Yonsei University105
- Tumor microenvironment8→257
- Immune system2→205
- Cancer research6→178
- Cancer cell1→37
- Immune checkpoint1→28
- Tumor microenvironment5→371
- Immune system4→262
- Cancer research8→246
- Immunotherapy2→234
- Cancer immunotherapy3→104
- Immune system1→49
- Cancer cell1→4
- Metastasis1→4
Where oncology is researched across South Korea
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing oncology patents in South Korea
South Korea oncology patent filing is accelerating — 367 filings from 129 assignees (2016–2025), led by Korea Advanced INST SCI & TECH, UNIV Yonsei IACF, UNIV Ulsan Found IND COOP; annual filings 4→73.
- Korea Advanced INST SCI & TECH27
- UNIV Yonsei IACF23
- UNIV Ulsan Found IND COOP19
- ASAN Found18
- Seoul NAT UNIV R&DB Foundation18
- GI Innovation17
- Genemedicine16
- Samsung15
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.